New drug shows promise for rare blood cancer with genetic flaw
NCT ID NCT03011372
First seen Nov 18, 2025 · Last updated Apr 29, 2026 · Updated 28 times
Summary
This study tested a drug called pemigatinib in 47 people with rare blood cancers that have a specific genetic change (FGFR1 rearrangement). The goal was to see if the drug could shrink or eliminate the cancer. The treatment helped some patients achieve a complete response, meaning no signs of cancer were found in their blood or bone marrow. This is an ongoing treatment, not a cure, as patients may need to continue medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MPN (MYELOPROLIFERATIVE NEOPLASMS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero-Universitaria Careggi (Aouc)
Florence, 50134, Italy
-
Centre Leon Berard
Lyon, 69373, France
-
Chu de Nice - Hospital L Archet
Nice, 06202, France
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Emory University - Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Franciscan St. Francis Health
Indianapolis, Indiana, 46237, United States
-
Guys and St Thomas Nhs Foundation Trust
London, SE1 9RT, United Kingdom
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Saint Louis
Paris, 75475, France
-
Iii Med. Abteilung For Hematologie and Onkologie Hanuscfhkrankenhaus
Vienna, 01140, Austria
-
Inselspital - Universitaetsspital Bern
Bern, 03010, Switzerland
-
Johannes Wesling Klinikum Minden
Minden, 32429, Germany
-
Kindai University Hospital
Osaka, 589-8511, Japan
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Md Anderson Cancer Center
Houston, Texas, 77030, United States
-
Medical University of Vienna
Vienna, 01090, Austria
-
Ntt Medical Center Tokyo
Tokyo, 141-8625, Japan
-
Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz
Linz, 04010, Austria
-
Ospedale Papa Giovanni Xxiii
Bergamo, 24127, Italy
-
Oxford University Hospitals Nhs Foundation Trust
Oxford, OX3 7LE, United Kingdom
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 2M9, Canada
-
Stanford Cancer Institute
Stanford, California, 94305, United States
-
Universitair Ziekenhuis (Uz) Leuven
Leuven, 03000, Belgium
-
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole
Toulouse, 31059, France
-
Universitatsklinikum Halle (Saale)
Halle, 06120, Germany
-
Universitatsklinikum Jena
Jena, 07740, Germany
-
Universitatsklinikum Leipzig
Leipzig, 04103, Germany
-
Universitatsspital Zurich
Zurich, 08091, Switzerland
-
University Hospital Mannheim
Mannheim, 68167, Germany
-
University Medical Center Rwth Aachen
Aachen, D-52074, Germany
-
University of Utah
Salt Lake City, Utah, 84112, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Weill Cornell Medical Centers
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.